메뉴 건너뛰기




Volumn 60, Issue 6, 2007, Pages 811-819

Pharmacokinetic modulation of oral etoposide by ketoconazole in patients with advanced cancer

Author keywords

Drug interaction; Etoposide; Ketoconazole; Pharmacokinetic modulation

Indexed keywords

ETOPOSIDE; KETOCONAZOLE;

EID: 34548565615     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00280-007-0428-5     Document Type: Article
Times cited : (20)

References (52)
  • 3
    • 0031661579 scopus 로고    scopus 로고
    • UGT1A1 genotypes and glucuronidation of SN-38, the active metabolite of irinotecan
    • Ando Y, Saka H, Asai G, Sugiura S, Shimokata K, Kamataki T (1998) UGT1A1 genotypes and glucuronidation of SN-38, the active metabolite of irinotecan. Ann Oncol 9:845-847
    • (1998) Ann Oncol , vol.9 , pp. 845-847
    • Ando, Y.1    Saka, H.2    Asai, G.3    Sugiura, S.4    Shimokata, K.5    Kamataki, T.6
  • 7
    • 0035461510 scopus 로고    scopus 로고
    • Saquinavir and ritonavir pharmacokinetics following combined ritonavir and saquinavir (soft gelatin capsules) administration
    • Buss N, Snell P, Bock J, Hsu A, Jorga K (2001) Saquinavir and ritonavir pharmacokinetics following combined ritonavir and saquinavir (soft gelatin capsules) administration. Br J Clin Pharmacol 52:255-264
    • (2001) Br J Clin Pharmacol , vol.52 , pp. 255-264
    • Buss, N.1    Snell, P.2    Bock, J.3    Hsu, A.4    Jorga, K.5
  • 8
    • 0021749639 scopus 로고
    • Nonintercalative antitumor drugs interfere with the breakage-reunion reaction of mammalian DNA topoisomerase II
    • Chen GL, Yang L, Rowe TC, Halligan BD, Tewey KM, Liu LF (1984) Nonintercalative antitumor drugs interfere with the breakage-reunion reaction of mammalian DNA topoisomerase II. J Biol Chem 259:13560-13566
    • (1984) J Biol Chem , vol.259 , pp. 13560-13566
    • Chen, G.L.1    Yang, L.2    Rowe, T.C.3    Halligan, B.D.4    Tewey, K.M.5    Liu, L.F.6
  • 11
    • 0033664759 scopus 로고    scopus 로고
    • Optimization of oral etoposide dosage in elderly patients with non-Hodgkin's lymphoma using the fraction of dose absorbed measured for each patient
    • el-Yazigi A, Ezzat A, Berry J, Raines DA, Yusuf A, al-Rawithi S, Legayada ES (2000) Optimization of oral etoposide dosage in elderly patients with non-Hodgkin's lymphoma using the fraction of dose absorbed measured for each patient. J Clin Pharmacol 40:153-160
    • (2000) J Clin Pharmacol , vol.40 , pp. 153-160
    • El-Yazigi, A.1    Ezzat, A.2    Berry, J.3    Raines, D.A.4    Yusuf, A.5    Al-Rawithi, S.6    Legayada, E.S.7
  • 13
    • 0026514714 scopus 로고
    • Factors affecting in vitro protein binding of etoposide in humans
    • Fleming RA, Evans WE, Arbuck SG, Stewart CF (1992) Factors affecting in vitro protein binding of etoposide in humans. J Pharm Sci 81:259-264
    • (1992) J Pharm Sci , vol.81 , pp. 259-264
    • Fleming, R.A.1    Evans, W.E.2    Arbuck, S.G.3    Stewart, C.F.4
  • 14
    • 0032904865 scopus 로고    scopus 로고
    • Effect of inhibitor depletion on inhibitory potency: Tight binding inhibition of CYP3A by clotrimazole
    • Gibbs MA, Kunze KL, Howald WN, Thummel KE (1999) Effect of inhibitor depletion on inhibitory potency: tight binding inhibition of CYP3A by clotrimazole. Drug Metab Dispos 27:596-599
    • (1999) Drug Metab Dispos , vol.27 , pp. 596-599
    • Gibbs, M.A.1    Kunze, K.L.2    Howald, W.N.3    Thummel, K.E.4
  • 15
    • 0023919948 scopus 로고
    • Identification of etoposide glucuronide as a major metabolite of etoposide in the rat and rabbit
    • Hande K, Anthony L, Hamilton R, Bennett R, Sweetman B, Branch R (1988) Identification of etoposide glucuronide as a major metabolite of etoposide in the rat and rabbit. Cancer Res 48:1829-1834
    • (1988) Cancer Res , vol.48 , pp. 1829-1834
    • Hande, K.1    Anthony, L.2    Hamilton, R.3    Bennett, R.4    Sweetman, B.5    Branch, R.6
  • 16
    • 0032697303 scopus 로고    scopus 로고
    • Inter- and intrapatient variability in etoposide kinetics with oral and intravenous drug administration
    • Hande K, Messenger M, Wagner J, Krozely M, Kaul S (1999) Inter- and intrapatient variability in etoposide kinetics with oral and intravenous drug administration. Clin Cancer Res 5:2742-2747
    • (1999) Clin Cancer Res , vol.5 , pp. 2742-2747
    • Hande, K.1    Messenger, M.2    Wagner, J.3    Krozely, M.4    Kaul, S.5
  • 22
    • 1942455361 scopus 로고    scopus 로고
    • Database analyses for the prediction of in vivo drug-drug interactions from in vitro data
    • Ito K, Brown HS, Houston JB (2004) Database analyses for the prediction of in vivo drug-drug interactions from in vitro data. Br J Clin Pharmacol 57:473-486
    • (2004) Br J Clin Pharmacol , vol.57 , pp. 473-486
    • Ito, K.1    Brown, H.S.2    Houston, J.B.3
  • 24
    • 0030477323 scopus 로고    scopus 로고
    • A pharmacodynamic evaluation of hematologic toxicity observed with etoposide phosphate in the treatment of cancer patients
    • Kaul S, Srinivas NR, Igwemezie LN, Barbhaiya RH (1996) A pharmacodynamic evaluation of hematologic toxicity observed with etoposide phosphate in the treatment of cancer patients. Semin Oncol 23:15-22
    • (1996) Semin Oncol , vol.23 , pp. 15-22
    • Kaul, S.1    Srinivas, N.R.2    Igwemezie, L.N.3    Barbhaiya, R.H.4
  • 28
    • 0026595179 scopus 로고
    • Effects of imidazole derivatives on cytochromes P450 from human hepatocytes in primary culture
    • Maurice M, Pichard L, Daujat M, Fabre I, Joyeux H, Domergue J, Maurel P (1992) Effects of imidazole derivatives on cytochromes P450 from human hepatocytes in primary culture. Faseb J 6:752-758
    • (1992) Faseb J , vol.6 , pp. 752-758
    • Maurice, M.1    Pichard, L.2    Daujat, M.3    Fabre, I.4    Joyeux, H.5    Domergue, J.6    Maurel, P.7
  • 31
    • 0030030762 scopus 로고    scopus 로고
    • Genetic variation in bilirubin UPD-glucuronosyltransferase gene promoter and Gilbert's syndrome
    • Monaghan G, Ryan M, Seddon R, Hume R, Burchell B (1996) Genetic variation in bilirubin UPD-glucuronosyltransferase gene promoter and Gilbert's syndrome. Lancet 347:578-581
    • (1996) Lancet , vol.347 , pp. 578-581
    • Monaghan, G.1    Ryan, M.2    Seddon, R.3    Hume, R.4    Burchell, B.5
  • 34
    • 0037974573 scopus 로고    scopus 로고
    • In vitro metabolism of midazolam, triazolam, nifedipine, and testosterone by human liver microsomes and recombinant cytochromes p450: Role of cyp3a4 and cyp3a5
    • Patki KC, Von Moltke LL, Greenblatt DJ (2003) In vitro metabolism of midazolam, triazolam, nifedipine, and testosterone by human liver microsomes and recombinant cytochromes p450: role of cyp3a4 and cyp3a5. Drug Metab Dispos 31:938-944
    • (2003) Drug Metab Dispos , vol.31 , pp. 938-944
    • Patki, K.C.1    Von Moltke, L.L.2    Greenblatt, D.J.3
  • 38
    • 22044452396 scopus 로고    scopus 로고
    • Studies on the interactions between drugs and estrogen. III. Inhibitory effects of 29 drugs reported to induce gynecomastia on the glucuronidation of estradiol
    • Satoh T, Tomikawa Y, Takanashi K, Itoh S, Yoshizawa I (2004) Studies on the interactions between drugs and estrogen. III. Inhibitory effects of 29 drugs reported to induce gynecomastia on the glucuronidation of estradiol. Biol Pharm Bull 27:1844-1849
    • (2004) Biol Pharm Bull , vol.27 , pp. 1844-1849
    • Satoh, T.1    Tomikawa, Y.2    Takanashi, K.3    Itoh, S.4    Yoshizawa, I.5
  • 40
    • 0021287609 scopus 로고
    • Pharmacokinetics of etoposide (VP16) in children and adolescents with refractory solid tumors
    • Sinkule JA, Hutson P, Hayes FA, Etcubanas E, Evans W (1984) Pharmacokinetics of etoposide (VP16) in children and adolescents with refractory solid tumors. Cancer Res 44:3109-3113
    • (1984) Cancer Res , vol.44 , pp. 3109-3113
    • Sinkule, J.A.1    Hutson, P.2    Hayes, F.A.3    Etcubanas, E.4    Evans, W.5
  • 42
    • 0027165501 scopus 로고
    • Prolonged oral etoposide in small cell lung cancer
    • Slevin ML, Joel SP (1993) Prolonged oral etoposide in small cell lung cancer. Ann Oncol 4:529-532
    • (1993) Ann Oncol , vol.4 , pp. 529-532
    • Slevin, M.L.1    Joel, S.P.2
  • 43
    • 0021986492 scopus 로고
    • Bioavailability and pharmacokinetics of etoposide (VP-16)
    • Smyth RD, Pfeffer M, Scalzo A, Comis RL (1985) Bioavailability and pharmacokinetics of etoposide (VP-16). Semin Oncol 12:48-51
    • (1985) Semin Oncol , vol.12 , pp. 48-51
    • Smyth, R.D.1    Pfeffer, M.2    Scalzo, A.3    Comis, R.L.4
  • 44
    • 0025169552 scopus 로고
    • Changes in the clearance of total and unbound etoposide in patients with liver dysfunction
    • Stewart CF, Arbuck SG, Fleming RA, Evans WE (1990) Changes in the clearance of total and unbound etoposide in patients with liver dysfunction. J Clin Oncol 8:1874-1879
    • (1990) J Clin Oncol , vol.8 , pp. 1874-9
    • Stewart, C.F.1    Arbuck, S.G.2    Fleming, R.A.3    Evans, W.E.4
  • 45
    • 0025119417 scopus 로고
    • Prospective evaluation of a model for predicting etoposide plasma protein binding in cancer patients
    • Stewart CF, Fleming RA, Arbuck SG, Evans WE (1990) Prospective evaluation of a model for predicting etoposide plasma protein binding in cancer patients. Cancer Res 50:6854-6856
    • (1990) Cancer Res , vol.50 , pp. 6854-6
    • Stewart, C.F.1    Fleming, R.A.2    Arbuck, S.G.3    Evans, W.E.4
  • 46
    • 2642575021 scopus 로고    scopus 로고
    • Pharmacokinetic optimisation of treatment with oral etoposide
    • Toffoli G, Corona G, Basso B, Boiocchi M (2004) Pharmacokinetic optimisation of treatment with oral etoposide. Clin Pharmacokinet 43:441-466
    • (2004) Clin Pharmacokinet , vol.43 , pp. 441-466
    • Toffoli, G.1    Corona, G.2    Basso, B.3    Boiocchi, M.4
  • 48
    • 0027103045 scopus 로고
    • What is the optimal dose and duration of treatment with etoposide? II. Comparative pharmacokinetic study of three schedules: 1 × 100 mg, 2 × 50 mg, and 4 × 25 mg of oral etoposide daily for 21 days
    • van der Gaast A, Vlastuin M, Kok TC, Splinter TA (1992) What is the optimal dose and duration of treatment with etoposide? II. Comparative pharmacokinetic study of three schedules: 1 × 100 mg, 2 × 50 mg, and 4 × 25 mg of oral etoposide daily for 21 days. Semin Oncol 19:8-12
    • (1992) Semin Oncol , vol.19 , pp. 8-12
    • Van Der Gaast, A.1    Vlastuin, M.2    Kok, T.C.3    Splinter, T.A.4
  • 49
    • 0142212226 scopus 로고    scopus 로고
    • Docetaxel and ketoconazole in advanced hormone-refractory prostate carcinoma: A phase I and pharmacokinetic study
    • Van Veldhuizen PJ, Reed G, Aggarwal A, Baranda J, Zulfiqar M, Williamson S (2003) Docetaxel and ketoconazole in advanced hormone-refractory prostate carcinoma: a phase I and pharmacokinetic study. Cancer 98:1855-1862
    • (2003) Cancer , vol.98 , pp. 1855-1862
    • Van Veldhuizen, P.J.1    Reed, G.2    Aggarwal, A.3    Baranda, J.4    Zulfiqar, M.5    Williamson, S.6
  • 50
    • 0037404036 scopus 로고    scopus 로고
    • Glucuronidation of etoposide in human liver microsomes is specifically catalyzed by UDP-glucuronosyltransferase 1A1
    • Watanabe Y, Nakajima M, Ohashi N, Kume T, Yokoi T (2003) Glucuronidation of etoposide in human liver microsomes is specifically catalyzed by UDP-glucuronosyltransferase 1A1. Drug Metab Dispos 31:589-595
    • (2003) Drug Metab Dispos , vol.31 , pp. 589-595
    • Watanabe, Y.1    Nakajima, M.2    Ohashi, N.3    Kume, T.4    Yokoi, T.5
  • 52
    • 25144450011 scopus 로고    scopus 로고
    • Effects of ketoconazole on glucuronidation by UDP-glucuronosyltransferase enzymes
    • Yong WP, Ramirez J, Innocenti F, Ratain MJ (2005) Effects of ketoconazole on glucuronidation by UDP-glucuronosyltransferase enzymes. Clin Cancer Res 11:6699-6704
    • (2005) Clin Cancer Res , vol.11 , pp. 6699-6704
    • Yong, W.P.1    Ramirez, J.2    Innocenti, F.3    Ratain, M.J.4


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.